Department of Pathology, Stanford University, Stanford, CA, USA.
Department of Pathology, University of California, San Francisco (UCSF), San Francisco, CA, USA.
Am J Clin Pathol. 2022 Feb 3;157(2):196-201. doi: 10.1093/ajcp/aqab111.
Small-volume biopsy-fine-needle aspiration biopsy (FNAB) with or without core biopsy-is in increasing use in diagnosis and management of lymphoma patients. Our objective was to survey the current practice in small-volume biopsy diagnosis of lymphoma, focusing on the interaction among hematopathologists and cytopathologists and the integration of FNAB, core biopsy, and flow cytometry studies at sign-out.
This study used a cross-sectional survey design employing the RedCap database distributed via nine pathology professional society email listservs. The survey consisted of 25 multiple-choice questions and several free text fields. In total, 128 pathologists participated.
Most respondents indicated that FNAB specimens in which lymphoma is a diagnostic consideration (FNAB-L) are seen daily or weekly (68/116; 58.6%). However, most institutions have separate hematopathology and cytopathology services (72/116; 62.1%) with inconsistent communication. When communication occurred, respondents were frequently inclined to reconsider their original diagnoses. Barriers identified included lack of communication, inadequate access to diagnostic studies, no formal subspecialty training, and various opinions regarding FNAB in diagnosing lymphoma.
This survey showed that FNAB-L specimens are common, with a lack of uniformity in how complementary fine-needle aspiration and core biopsy specimens or flow immunophenotyping results are shared across hematopathology and cytopathology services.
小体积活检——细针抽吸活检（FNAB）联合或不联合核心活检——在淋巴瘤患者的诊断和治疗中越来越多地被应用。我们的目的是调查目前在小体积活检诊断淋巴瘤方面的实践情况，重点关注血液病理学家和细胞病理学家之间的相互作用，以及在报告时整合 FNAB、核心活检和流式细胞术研究。
本研究采用横断面调查设计，使用通过九个病理学专业协会电子邮件列表分发的 RedCap 数据库。该调查包括 25 个多项选择题和几个自由文本字段。共有 128 名病理学家参与。
大多数受访者表示，淋巴瘤是诊断考虑因素的 FNAB 标本（FNAB-L）每天或每周都能看到（68/116；58.6%）。然而，大多数机构都有独立的血液病理学和细胞病理学服务（72/116；62.1%），沟通不一致。当沟通发生时，受访者经常倾向于重新考虑他们的原始诊断。确定的障碍包括缺乏沟通、获取诊断研究的机会不足、没有正式的专业培训以及对 FNAB 诊断淋巴瘤的各种意见。
这项调查表明，FNAB-L 标本很常见，但在血液病理学和细胞病理学服务之间如何共享补充性细针抽吸和核心活检标本或流式免疫表型结果方面缺乏一致性。
